Viridian Therapeutics, Inc.
VRDN
$28.68
$0.270.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 132.00K | 70.57M | 75.00K | 72.00K | 72.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 132.00K | 70.57M | 75.00K | 72.00K | 72.00K |
| Cost of Revenue | 92.71M | 86.26M | 86.63M | 5.75M | 71.96M |
| Gross Profit | -92.58M | -15.69M | -86.55M | -5.68M | -71.89M |
| SG&A Expenses | 33.67M | 24.32M | 20.22M | 17.10M | 15.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 126.38M | 110.58M | 106.84M | 93.94M | 87.54M |
| Operating Income | -126.25M | -40.01M | -106.77M | -93.87M | -87.47M |
| Income Before Tax | -120.36M | -34.60M | -100.74M | -86.91M | -79.73M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -120.36M | -34.60M | -100.74M | -86.91M | -79.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -120.36M | -34.60M | -100.74M | -86.91M | -79.73M |
| EBIT | -126.25M | -40.01M | -106.77M | -93.87M | -87.47M |
| EBITDA | -126.13M | -39.90M | -106.65M | -93.75M | -87.35M |
| EPS Basic | -1.07 | -0.34 | -1.00 | -0.87 | -0.81 |
| Normalized Basic EPS | -0.82 | -0.26 | -0.77 | -0.67 | -0.62 |
| EPS Diluted | -1.07 | -0.34 | -1.00 | -0.87 | -0.81 |
| Normalized Diluted EPS | -0.82 | -0.26 | -0.77 | -0.67 | -0.62 |
| Average Basic Shares Outstanding | 94.38M | 81.78M | 81.59M | 81.34M | 80.05M |
| Average Diluted Shares Outstanding | 94.38M | 81.78M | 81.59M | 81.34M | 80.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |